September 24, 2018 / 1:53 PM / 3 months ago

BRIEF-Roche's Genentech Presents Interim Results Of Phase III Tecentriq Trial

Sept 24 (Reuters) - Roche Holding AG:

* PHASE III TRIAL OF GENENTECH’S TECENTRIQ IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY SHOWED REDUCED RISK OF DISEASE WORSENING OR DEATH IN A TYPE OF PREVIOUSLY UNTREATED ADVANCED LUNG CANCER

* INTERIM ANALYSIS SHOWED THAT TECENTRIQ AND CHEMOTHERAPY REDUCED RISK OF DISEASE WORSENING OR DEATH (PROGRESSION-FREE SURVIVAL, PFS) BY 40 PERCENT COMPARED WITH CHEMOTHERAPY ALONE

* SAYS ON TECENTRIQ TRIAL - AT THIS INTERIM ANALYSIS STATISTICAL SIGNIFICANCE HAS NOT YET BEEN MET Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below